APDN Quote, Financials, Valuation and Earnings

OncoCyte has a net margin of -405.45% compared to Applied DNA Sciences's net margin of -11733.04%. Applied DNA Sciences's return on equity of -116.43% beat OncoCyte's return on equity of -211.42%.

Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 13057.9%. On the other hand OncoCyte has an analysts' consensus of $4.13 which suggests that it could grow by 80.13%. Given that Applied DNA Sciences has higher upside potential than OncoCyte, analysts believe Applied DNA Sciences is more attractive than OncoCyte.

Applied DNA Sciences has a beta of 0.397, which suggesting that the stock is 60.306% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.313%.

Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Applied DNA Sciences quarterly revenues are $813.1K, which are larger than OncoCyte quarterly revenues of $115K. Applied DNA Sciences's net income of -$3.3M is higher than OncoCyte's net income of -$13.5M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.26x versus 34.81x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of -405.45% compared to Applied DNA Sciences's net margin of -209.38%. Applied DNA Sciences's return on equity of -116.43% beat ProPhase Labs's return on equity of -59.59%.

Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 13057.9%. On the other hand ProPhase Labs has an analysts' consensus of -- which suggests that it could grow by 2437.72%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.

Applied DNA Sciences has a beta of 0.397, which suggesting that the stock is 60.306% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.304, suggesting its less volatile than the S&P 500 by 130.392%.

Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Applied DNA Sciences quarterly revenues are $813.1K, which are smaller than ProPhase Labs quarterly revenues of $3.1M. Applied DNA Sciences's net income of -$3.3M is higher than ProPhase Labs's net income of -$6.6M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.26x versus 1.06x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -405.45% compared to Applied DNA Sciences's net margin of 13.08%. Applied DNA Sciences's return on equity of -116.43% beat Veracyte's return on equity of -0.84%.

Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 13057.9%. On the other hand Veracyte has an analysts' consensus of $43.22 which suggests that it could fall by -0.43%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.

Applied DNA Sciences has a beta of 0.397, which suggesting that the stock is 60.306% less volatile than S&P 500. In comparison Veracyte has a beta of 1.706, suggesting its more volatile than the S&P 500 by 70.591%.

Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Applied DNA Sciences quarterly revenues are $813.1K, which are smaller than Veracyte quarterly revenues of $115.9M. Applied DNA Sciences's net income of -$3.3M is lower than Veracyte's net income of $15.2M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.26x versus 7.74x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -405.45% compared to Applied DNA Sciences's net margin of -56.4%. Applied DNA Sciences's return on equity of -116.43% beat XWELL's return on equity of -71.82%.

Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 13057.9%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 360.53%. Given that Applied DNA Sciences has higher upside potential than XWELL, analysts believe Applied DNA Sciences is more attractive than XWELL.

Applied DNA Sciences has a beta of 0.397, which suggesting that the stock is 60.306% less volatile than S&P 500. In comparison XWELL has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.765%.

Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Applied DNA Sciences quarterly revenues are $813.1K, which are smaller than XWELL quarterly revenues of $8.4M. Applied DNA Sciences's net income of -$3.3M is higher than XWELL's net income of -$4.8M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.26x versus 0.20x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.